Lanao J M, Dominguez-Gil A, Tabernero J M, Sanchez Tomero J A
Int J Clin Pharmacol Biopharm. 1979 Aug;17(8):357-60.
The pharmacokinetics of Amikacin (BB-K8) was studied after administration in an i.v. bolus injection of 7.5 mg/kg to 10 patients with terminal renal impairment undergoing dialysis sessions of 6 hours. A two-compartment kinetic model has been used to describe the bi-phasic decrease of the plasma concentrations of the antibiotic thus establishing the amounts of the antibiotic in the central and peripheral compartments, its elimination being principally through the kidney. During the hemodialysis sessions the average pharmacokinetic parameters of the Amikacin were: alpha = 3.422 h-1 beta = 0.176 h-1 K12 = 1.820 h-1 K21 = 1.327 H-1, K13 = 0.450 h-1, Vc = 9.242 l Vp = 11.455 l Vdss = 20.697 l and delta = 0.377 l/kg. A dosage regimen as a function of the pharmacokinetic parameters is established for patients with terminal renal impairment which guarantees safe and efficient concentrations of the antibiotic.
对10例晚期肾功能损害且正在接受6小时透析治疗的患者静脉推注7.5mg/kg的丁胺卡那霉素（BB-K8）后，研究了其药代动力学。采用二室动力学模型描述抗生素血浆浓度的双相下降，从而确定抗生素在中央室和周边室的量，其消除主要通过肾脏。在血液透析期间，丁胺卡那霉素的平均药代动力学参数为：α = 3.422 h-1，β = 0.176 h-1，K12 = 1.820 h-1，K21 = 1.327 H-1，K13 = 0.450 h-1，Vc = 9.242 l，Vp = 11.455 l，Vdss = 20.697 l，δ = 0.377 l/kg。为晚期肾功能损害患者建立了根据药代动力学参数的给药方案，以确保抗生素的安全有效浓度。
